Status:
COMPLETED
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
Lead Sponsor:
Incyte Corporation
Conditions:
Psoriasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12...
Eligibility Criteria
Inclusion
- Plaque psoriasis involving up to 2 to 20% Body Surface Area
Exclusion
- Lesions solely involving intertriginous areas, the scalp or the face
- Systemic therapy for their psoriasis
- Pustular psoriasis or erythroderma
- Currently on other topical agents or Ultraviolet B (UVB) therapy within 2 weeks of the first dose of study medication
- Started or discontinued therapy within 2 months of Screening with agents that can exacerbate psoriasis
- Receiving systemic triazole antifungals except fluconazole
Key Trial Info
Start Date :
October 28 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 26 2009
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT00778700
Start Date
October 28 2008
End Date
June 26 2009
Last Update
February 9 2022
Active Locations (28)
Enter a location and click search to find clinical trials sorted by distance.
1
Hot Springs, Arkansas, United States
2
Los Angeles, California, United States
3
San Diego, California, United States
4
Santa Monica, California, United States